Dyadic International, Inc. is a biotechnology platform company that develops, manufactures, and commercializes proteins and enzymes in the United States. It offers the Dapibus Protein Production Platform, a proprietary expression system for non-animal proteins and enzymes for non-pharmaceutical markets such as life sciences, food and nutrition, and bio-industrial sectors, and the C1 Protein Production Platform, a thermophilic fungal platform for large-scale protein production. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; a license agreement with Rubic One Health for livestock vaccines; a sub-license agreement with Phibro Animal Health/Abic Biological Laboratories for livestock disease vaccines and treatments; and a collaboration with Scripps Research on monoclonal antibody and vaccine candidates targeting hantaviruses. Founded in 1979, Dyadic International, Inc. is headquartered in Jupiter, Florida.
Dyadic International reports Q2 2026 results and commercial progress
Dyadic International reported second quarter 2026 revenue of approximately $961,000, essentially flat compared to $967,000 a year earlier, while its net loss widened to $2.1 million from $1.8 million. The company highlighted progress across its life sciences, food and nutrition, and bioindustrial segments, including initial product shipments to IBT Bioservices, pilot sales of recombinant transferrin and growth factors for cultivated meat, and commercial sales of non-animal chymosin by partner Enzymes. Dyadic also disclosed substantial doubt about its ability to continue as a going concern under accounting standard ASC 205-3, citing the need for additional capital, though it noted compliance with convertible note covenants and a maturity date of December 31, 2027. Management said it is evaluating financing alternatives including non-dilutive and strategic sources such as licensing, milestones, and partnerships.
Dyadic International Q2 EPS misses by $0.03, revenue misses by $0.67M
Dyadic International reported second quarter 2026 financial results with a GAAP loss per share of $0.06, missing expectations by $0.03, and revenue of $0.96 million, down 1.0% year over year and missing estimates by $0.67 million. Research and development expenses fell 47.2% to $332,621 due to fewer active internal research initiatives, while general and administrative expenses rose 17.6% to $1,689,863 on higher rebranding, business development, legal, and accounting costs. Loss from operations widened 18.8% to $2,054,204, driven by higher cost of revenue and G&A expenses, partially offset by lower R&D spending.
Dyadic regains compliance with Nasdaq listing requirements
Dyadic International announced on Friday that it has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). The company's common stock will continue to be listed and traded on the Nasdaq Capital Market. Shares fell 6.92%.
Dyadic International Soars Over 20% After Major Shareholder Francisco Trust Files to Sell More Than 364,000 Shares
Dyadic International shares surged over 21% on Tuesday after a Form 144 filing with the SEC on July 21, 2026, indicated that major shareholder Francisco Trust intends to sell more than 364,000 shares with an aggregate market value of approximately $539,000. As of July 6, 2026, Francisco Trust owned 4,328,045 shares, representing 11.58% of the company's outstanding common stock. Dyadic, which does business as Dyadic Applied BioSolutions, reported first-quarter 2026 revenue of $1.11 million, up from $393,572 a year earlier, driven by higher research and development revenue from the Proliant Agreement, increased grant funding from CEPI and the Gates Foundation, and a milestone payment under the Inzymes Agreement. The stock closed at $1.47, up 21.49%.
Dyadic Highlights C1 Platform Validation Across Global Health Collaborations
Dyadic International highlighted continued progress across multiple global health collaborations that further validate its proprietary C1 protein production platform. The company has received the full $3.1 million Gates Foundation grant, including a final payment of $738,743 in June 2026, to fund research on monoclonal antibodies for RSV and malaria, where C1-produced antibodies showed binding and neutralization comparable to traditional CHO cell systems with higher yields and lower projected costs. In a $4.5 million collaboration with CEPI and Fondazione Biotecnopolo di Siena, researchers demonstrated plasmid-to-purified-protein production in approximately 15 days using C1. Dyadic also announced a collaboration with Scripps Research on Bundibugyo Ebola preparedness, with initial purified antigen samples expected by the end of July 2026, and continues to expand awareness through the European Vaccines Hub and other preparedness initiatives. The company believes C1 can address biologics manufacturing bottlenecks and support multiple avenues for value creation across an addressable opportunity of more than $25 billion within the global biologics market.
Dyadic Expands IP Protection and Business Development Activities in Japan
Dyadic International announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant protection to the company's global intellectual property portfolio and reinforces its C1 and Dapibus microbial production platforms. As part of its international growth strategy, Dyadic engaged Intralink to support expansion efforts in Japan, generating targeted engagement opportunities with prospective partners across biotechnology, pharmaceutical, food, nutrition, and other sectors. President and COO Joe Hazelton is scheduled to meet with several high-potential partners during a business development visit in early July. The company believes its enhanced IP protection and local business development support position it to capitalize on growing demand for scalable recombinant protein solutions in Japan's advanced biotechnology market.
United States